Erschienen in:
01.10.2014 | Original Article – Clinical Oncology
Prognostic impact of angiopoietin-2 in multiple myeloma
verfasst von:
Constantina A. Pappa, Michael G. Alexandrakis, Anna Boula, Aspasia Thanasia, Ioannis Konsolas, Athanasios Alegakis, George Tsirakis
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 10/2014
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Angiogenesis is an essential process for the expansion of multiple myeloma (MM). Angiopoietin-2 (Ang-2), Ang-1 and their receptor possess important roles in this procedure. The aim of the study was to measure serum levels of Ang-2 along with known markers of angiogenesis and to estimate their prognostic impact on the survival.
Methods
Bone marrow microvascular density (MVD), estimated by CD31, and circulating levels of known angiogenic factors Ang-2, interleukin-6, soluble CD105 and platelet-derived growth factor-AB, measured by ELISA, were measured in 77 newly diagnosed patients with active MM and in 57 of them who responded to chemotherapy.
Results
All measured parameters were increased in MM patients, were also increasing in advanced disease and decreased after effective treatment. Ang-2 correlated positively with the other angiogenic factors and MVD. Moreover, Ang-2 values above the median were accompanied by worse survival.
Conclusion
Ang-2 correlates strongly with the angiogenic process and its serum levels are importantly prognostic for survival, highlighting the role of angiopoietins pathway in the biology of MM.